sulfaphenazole has been researched along with torsemide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Birkett, DJ; Miners, JO; Rees, DL; Valente, L; Veronese, ME | 1 |
| Birkett, DJ; Coulter, S; Goldstein, JA; Miners, JO | 1 |
3 other study(ies) available for sulfaphenazole and torsemide
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diuretics; Humans; In Vitro Techniques; Kinetics; Liver; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfaphenazole; Sulfonamides; Tolbutamide; Torsemide | 1995 |
Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diuretics; Enzyme Inhibitors; Genetic Variation; Humans; Microsomes, Liver; Saccharomyces cerevisiae; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfaphenazole; Sulfonamides; Torsemide | 2000 |